EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B Leighl iD, Hiroaki Akamatsu iD, Sun Min Lim iD, Ying Cheng iD, Anna R Minchom iD, Melina E Marmarelis iD, Rachel E Sanborn iD, James Chih-Hsin Yang iD, Baogang Liu, Thomas John iD, Bartomeu Massutí iD, Alexander I Spira iD und 37 weitere

Journal of Clinical Oncology · 20.10.2024 · 42 (30) · 3593-3605

DOI: 10.1200/jco.24.01001 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2024. Verfasst von Natasha B Leighl und 48 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor ( EGFR )–mutated advanced non–small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy. PATIENTS AND METHODS Patients with EGFR -mutated advanced NSCLC who progressed after osimertinib and platinum-based chemotherapy were randomly assigned 1:1 to receive subcutaneous or intravenous amivantamab, both combined with lazertinib. Coprimary pharmacokinetic noninferiority end points were trough concentrations (C trough ; on cycle-2-day-1 or cycle-4-day-1) and cycle-2 area under the curve (AUC D1-D15 ). Key secondary end points were objective response rate (ORR) and progression-free survival (PFS). Overall survival (OS) was a predefined exploratory end point. RESULTS Overall, 418 patients underwent random assignment (subcutaneous group, n = 206; intravenous group, n = 212). Geometric mean ratios of C trough for subcutaneous to intravenous amivantamab were 1.15 (90% CI, 1.04 to 1.26) at cycle-2-day-1 and 1.42 (90% CI, 1.27 to 1.61) at cycle-4-day-1; the cycle-2 AUC D1-D15 was 1.03 (90% CI, 0.98 to 1.09). ORR was 30% in the subcutaneous and 33% in the intravenous group; median PFS was 6.1 and 4.3 months, respectively. OS was significantly longer in the subcutaneous versus intravenous group (hazard ratio for death, 0.62; 95% CI, 0.42 to 0.92; nominal P = .02). Fewer patients in the subcutaneous group experienced infusion-related reactions (IRRs; 13% v 66%) and venous thromboembolism (9% v 14%) versus the intravenous group. Median administration time for the first infusion was reduced to 4.8 minutes (range, 0-18) for subcutaneous amivantamab and to 5 hours (range, 0.2-9.9) for intravenous amivantamab. During cycle-1-day-1, 85% and 52% of patients in the subcutaneous and intravenous groups, respectively, considered treatment convenient; the end-of-treatment rates were 85% and 35%, respectively. CONCLUSION Subcutaneous amivantamab-lazertinib demonstrated noninferiority to intravenous amivantamab-lazertinib, offering a consistent safety profile with reduced IRRs, increased convenience, and prolonged survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationAntibodies, BispecificMorpholinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAcrylamidesAdministration, IntravenousInjections, SubcutaneousProgression-Free SurvivalPyrazolesPyrimidines

Substanzen

AcrylamidesErbB ReceptorsAntibodies, BispecificMorpholinesEGFR protein, humanamivantamablazertinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Jilin Cancer Hospital, Changchun, China.
  • Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.
  • Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Thomas John, Bartomeu Massutí, Alexander I Spira, Se-Hoon Lee, Juan Li, Silvia Novello, Ji-Youn Han, Rohit Joshi, Enriqueta Felip, Pei Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Laurent Greillier, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Kowalski, Mehmet Ali Nahit Şendur, Ali Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Joshua M Bauml, Antonio Passaro

Zitieren

APA

Leighl, N. B., Akamatsu, H., Lim, S. M., Cheng, Y., Minchom, A. R., Marmarelis, M. E., Sanborn, R. E., Chih-Hsin Yang, J., Liu, B., John, T., Massutí, B., Spira, A. I., Lee, S. H., Wang, J., Li, J., Liu, C., Novello, S., Kondo, M., Tamiya, M., …, & PALOMA-3 Investigators (2024). Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. Journal of Clinical Oncology, 42(30), 3593-3605. https://doi.org/10.1200/jco.24.01001

Vancouver

Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. Journal of Clinical Oncology. 2024;42(30):3593-3605. doi:10.1200/jco.24.01001

BibTeX
@article{Leighl2024,
  author = {Leighl, Natasha B and Akamatsu, Hiroaki and Lim, Sun Min and Cheng, Ying and Minchom, Anna R and Marmarelis, Melina E and Sanborn, Rachel E and Chih-Hsin Yang, James and Liu, Baogang and John, Thomas and Massutí, Bartomeu and Spira, Alexander I and Lee, Se-Hoon and Wang, Jialei and Li, Juan and Liu, Caigang and Novello, Silvia and Kondo, Masashi and Tamiya, Motohiro and Korbenfeld, Ernesto and Moskovitz, Mor and Han, Ji-Youn and Alexander, Mariam and Joshi, Rohit and Felip, Enriqueta and Voon, Pei Jye and Danchaivijitr, Pongwut and Hsu, Ping-Chih and Silva Melo Cruz, Felipe José and Wehler, Thomas and Greillier, Laurent and Teixeira, Encarnação and Nguyen, Danny and Sabari, Joshua K and Qin, Angel and Kowalski, Dariusz and Şendur, Mehmet Ali Nahit and Xie, John and Ghosh, Debopriya and Alhadab, Ali and Haddish-Berhane, Nahor and Clemens, Pamela L and Lorenzini, Patricia and Verheijen, Remy B and Gamil, Mohamed and Bauml, Joshua M and Baig, Mahadi and Passaro, Antonio and PALOMA-3 Investigators, PALOMA-3 Investigators},
  title = {Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {30},
  pages = {3593--3605},
  doi = {10.1200/jco.24.01001}
}
Kostenlos starten →